Iron Supplementation of Marginally Low Birth Weight Infants
NCT00558454 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 380
Last updated 2020-03-26
Summary
Iron is essential for brain development and there is a well established association between iron deficiency in infants and poor neurological development. In Sweden, about 5% of newborns have low birth weight (\< 2500 g). Due to small iron stores at birth and rapid postnatal growth, they have increased risk of iron deficiency and it is therefore important to prevent iron deficiency in this population. However, excessive iron supplementation can have adverse effects in infants such as growth impairment. In a randomized, controlled trial, we are investigating the effects of 0, 1 or 2 mg/kg/d of iron on brain myelination, cognitive development and growth in low birth weight infants.
Conditions
- Anemia
- Iron-Deficiency
- Child Behavior Disorders
- Cognitive Manifestations
Interventions
- DRUG
-
Iron
Ferrous succinate mixture
Sponsors & Collaborators
-
The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)
collaborator OTHER_GOV -
Jerring Foundation, Sweden
collaborator UNKNOWN -
Oskar Foundation
collaborator OTHER -
Umeå University
lead OTHER
Principal Investigators
-
Magnus Domellöf, MD, PhD · Umeå University, Sweden
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 39 Days
- Max Age
- 45 Days
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-03-31
- Primary Completion
- 2008-06-30
- Completion
- 2014-11-30
Countries
- Sweden
Study Locations
More Related Trials
-
Use of Melatonin for Neuroprotection in Asphyxiated Newborns
NCT03806816 ·Status: UNKNOWN ·Phase: NA
-
High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study
NCT00589953 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage
NCT03914690 ·Status: COMPLETED ·Phase: PHASE2
-
Infant Brain Study Follow-Up at 3 and 4 Years of Age
NCT02619006 ·Status: TERMINATED
-
Identification of Jaundice in Newborns Using Smartphones
NCT04182555 ·Status: COMPLETED ·Phase: NA
-
Erythropoietin Treatment in Extremely Low Birth Weight Infants
NCT00593801 ·Status: COMPLETED ·Phase: NA
-
umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity (BORN)
NCT05100212 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome
NCT03110341 ·Status: UNKNOWN ·Phase: PHASE3
-
Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia
NCT06984445 ·Status: RECRUITING
-
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
NCT01096784 ·Status: COMPLETED ·Phase: PHASE2
-
Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity
NCT00339001 ·Status: UNKNOWN
-
Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy
NCT01904786 ·Status: WITHDRAWN ·Phase: PHASE1
-
Does Erythropoietin Improve Outcome in Very Preterm Infants?
NCT00413946 ·Status: COMPLETED ·Phase: PHASE2
-
Hepcidin Levels in Preterm Infants
NCT01539356 ·Status: COMPLETED
-
Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage
NCT03390530 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution
NCT06624709 ·Status: RECRUITING ·Phase: NA
-
Erythropoietin in Premature Infants to Prevent Encephalopathy
NCT02550054 ·Status: TERMINATED ·Phase: PHASE2
-
RBC Irradiation, Anemia and Gut Injury
NCT02741648 ·Status: ACTIVE_NOT_RECRUITING
-
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
NCT02551003 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
NCT02050971 ·Status: UNKNOWN ·Phase: PHASE1
-
Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin
NCT01207778 ·Status: COMPLETED
-
Darbepoetin Administration to Preterm Infants
NCT00334737 ·Status: COMPLETED ·Phase: PHASE2
-
Cerebral Haemodynamic Changes by Red Blood Cell Transfusion in Neonates
NCT03983694 ·Status: COMPLETED
-
Iron and Retinopathy of Prematurity (ROP)
NCT05133999 ·Status: COMPLETED
-
The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells
NCT03696745 ·Status: UNKNOWN ·Phase: PHASE1